The Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response and Food and Drug Administration today extended the shelf life for the monoclonal antibody therapy etesevimab, which currently must be administered with bamlanivimab. Unopened vials of etesevimab may be stored for an additional six months from the labeled date of expiry. The extension applies to all unopened vials of etesevimab that have been stored as detailed in the fact sheet for health care providers and emergency use authorization for bamlanivimab and etesevimab administered together.

Related News Articles

News
The U.S. District Court for the Eastern District of Missouri today granted a preliminary injunction preventing the Centers for Medicare & Medicaid Services…
Headline
A two-dose series of the Pfizer-BioNTech COVID-19 vaccine was 100% effective against COVID-19 in 12-15 year olds more than four months after the second dose in…
Headline
Centers for Disease Control and Prevention Director Rochelle Walensky, M.D., Friday expanded eligibility for COVID-19 booster shots to include all adults…
Headline
The Food and Drug Administration today authorized a single booster dose of the Pfizer or Moderna COVID-19 vaccine for all individuals aged 18 or older at…
Headline
The federal government will purchase 10 million treatment courses of the COVID-19 oral antiviral Paxlovid from Pfizer if the Food and Drug Administration…
Headline
The Occupational Safety and Health Administration has suspended activities related to implementation and enforcement of its Emergency Temporary Standard on…